ReviewFrontiers in immunology2026
Tissue repair in the central nervous system: the epigenetic programming of regulatory T cells.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regulatory T cells are well known for their immunomodulatory role but also their regenerative function is increasingly recognized across multiple tissue types including skeletal muscle, lung and the central nervous system (CNS). In the CNS, Tregs have been shown to promote oligodendrocyte precursor cell differentiation and their interaction with microglia supports a pro-regenerative microenvironment in the brain. The suppressive function of Tregs is highly dependent on the epigenetic signature, specifically DNA methylation, of certain network of Treg-related genes including FOXP3, CTLA4, IKZF2, IKZF4 and TNFRSF18 which collectively function to maintain Treg cell lineage and stability. Whether a similar or the same epigenetic program also influences the regenerative capacity of Tregs remains unknown, and the methylation status of regenerative genes such as AREG, NT3, and osteopontin has never been characterized. Understanding the epigenetic regulation of Tregs in this respect is relevant for demyelinating disease such as multiple sclerosis (MS). MS is characterized by chronic neuroinflammation and neurodegeneration associated with remyelination failure. In MS, Treg suppressive function is compromised and epigenetic dysregulation at key Treg loci has been reported. However, the role of those loci in repair is unknown and the methylation status of regenerative genes in MS Tregs has not been studied. This review examines the evidence for Treg-mediated CNS repair, the epigenetic mechanisms controlling Treg identity, and highlights the epigenetic regulation of Treg regenerative genes as a critical gap in the field with potential implications for remyelination failure in MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.